RELAPSING - REMITTING MULTIPLE SCLEROSIS

This study tests a computer program called PRIMUS that helps neurologists choose treatments for people with relapsing-remitting multiple sclerosis (MS). The tool uses data from past patients to predict how the disease might progress under different therapies. Doctors in some clin…

This study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a sh…

This early study tests a new treatment called S103 (BCMA-CAR T cells) in 9 adults with progressive or hard-to-treat multiple sclerosis (MS). The main goal is to see if the treatment is safe and to find the best dose. Researchers will also look for early signs that it might help c…

This early-stage trial tests a new treatment for multiple sclerosis (MS) that combines a drug called ofatumumab with NK042, a therapy made from immune cells donated by healthy people. The study will include 20 adults with different types of MS and will primarily check for safety …

This study tests whether giving two strong medications one after the other—rituximab then cladribine—is safe and works well for people with relapsing-remitting multiple sclerosis (MS). Sixty adults aged 18 to 50 with active MS within the last year will receive the treatment and b…

This study tests whether clemastine fumarate, an over-the-counter allergy medication, can repair damaged nerve insulation (myelin) in people with multiple sclerosis. About 44 adults with relapsing-remitting MS will receive either the drug or a placebo for 3 months, then all will …

This study tests a six-month personalized telenursing program for 110 adults with multiple sclerosis. Participants receive monthly educational videos and nurse-led video calls to help them better understand their health and navigate the healthcare system. The goal is to improve h…

This pilot study tests whether repetitive transcranial magnetic stimulation (rTMS) is safe and helpful for depression and fatigue in adults with multiple sclerosis (MS). About 20 participants will receive daily rTMS sessions for 5 days, with assessments before, after, and at a 4-…

This study will test whether a 12-week progressive resistance training program can improve brain health and daily function in people with relapsing-remitting multiple sclerosis. Thirty participants will be randomly assigned to either an exercise group or a control group. Research…

This study tests whether sensory integration therapy can improve walking stability and quality of life in people with multiple sclerosis (MS). About 44 adults with relapsing-remitting MS will be randomly assigned to receive either the therapy or standard care. The therapy uses sp…

This study looks at how different types of exercise—aerobic and resistance training—affect the immune system and physical abilities in people with relapsing-remitting multiple sclerosis (MS). Researchers will measure changes in blood markers of inflammation and functional tests l…

This study looks at whether the time of day you eat can affect brain health in people with multiple sclerosis. Twenty-two adults with MS will follow a daily eating schedule for a set period. Researchers will measure markers of nerve health and inflammation in the blood. A small g…

This study will test whether a 12-week progressive resistance training program can improve brain health in people with relapsing-remitting multiple sclerosis. Researchers will measure brain volume and a nerve damage marker in the blood. The trial involves 26 participants and aims…

This study looks at how treatment failure impacts the quality of life, anxiety, depression, and daily activities of 150 adults with relapsing-remitting multiple sclerosis. Researchers will use questionnaires to measure patients' well-being and their experience with care. The goal…